London, UK (PRWEB) March 06, 2015
In 2014, the FDA approved 44 drugs, with 17 of them being first–in-class. AstraZeneca tops the list scoring 4 drug approvals in the USA. The infectious disease field obtained over 25% of all FDA approved drug products, followed by oncology therapy with 18% of the total. First-in-class mechanisms such as anti-PCSK9, anti-PD1 and CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and Pembrolizumab have been approved by the FDA to treat metastatic melanoma, and at present, they are being investigated in manifold big oncology segments such as non-small-cell lung carcinoma, renal cell carcinoma, and Hodgkin’s lymphoma. There is a fierce competition between Amgen and Sanofi/Regeneron in introducing new PCSK9 inhibitors, namely evolocumab and alirocumab, on the market in the USA, respectively, to treat elevated levels of low-density lipoprotein cholesterol. Amgen took the lead in August 2014 by becoming the first firm to seek US approval for its PCSK9 inhibitor evolocumab and Sanofi leveled that playing field by purchasing a priority review voucher that could accelerate the FDA review.
Leading pharma companies keep on boosting the productivity by focusing on selected therapy fields and markets, M&As, consolidation activities in vaccines, animal health and consumer healthcare businesses, etc. Metabolic and cardiovascular segments are still attractive, and the top pharma companies are bringing novel product options with better economics and patients’ compliances.
In-demand report “Global Pharma US & EU Outlook 2015: First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies” worked out by MP Advisors has been recently published at MarketPublishers.com.
Title: Global Pharma US & EU Outlook 2015: First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies
Published: January, 2015
Price: US$ 2,000.00
The research study provides a comprehensive analysis of selective large-cap companies worldwide, focusing mainly on the USA and the EU. It reviews the most promising late-stage drug candidates, explores the competitive scenario, and identifies key therapy domains where leadership is poised to be created through innovation. The report also provides forecasts for the leading marketed drugs where competition and/or regulatory policies are likely to change the dynamics, and assesses the potential effect of a slew of crucial oncoming milestones on the industry.
Companies mentioned include: Merck, GlaxoSmithKline, Merck KGaA, AstraZeneca, Novartis, and Novo Nordisk.
- Overview of the pharmaceutical business and the top players in the field.
- Deep review of the drugs in late stage development pipeline.
- Essential information on the marketed products.
- Overview of the latest drug product launches.
- Analysis of the competitive landscape.
- In-depth discussion of the dominant players’ performance including comprehensive profiles covering their offerings, strategies, developments, etc.
- Insightful exploration of drug clinical milestones.
- Detailed examination of the key market trends and pressing issues.
- Look at the regulatory landscape.
- Future outlook.
More in-demand reports by the publisher can be found at MP Advisors page.